Clinical trials: 5-FU
Pancreatic Neoplasms
Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer
Primary Objective: To demonstrate that the addition of oxaliplatin to 5-Fluorouracil (5-FU) and Leucovorin (LV) will improve the Progression-Free Survival (PFS).
- Trial name
- NCT01121848
- Testing
- Leucovorin, OXALIPLATIN, 5-Fluorouracil
- Where
- 15 sites in Canada
- Volunteers
- 108 people
- Sponsor
- Sanofi
Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
Durvalumab and Tremelimumab in combination with first-line chemotherapy in the following indications: Ovarian/peritoneal/fallopian tube cancer, SCCHN, TNBC, SCLC and gastric/GEJ cancer, PDAC, ESCC.
- Conditions
- Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Stomach Neoplasms, Triple Negative Breast Neoplasms
- Trial name
- NCT02658214
- Testing
- paclitaxel + carboplatin, carboplatin + etoposide, gemcitabine + carboplatin
- Where
- 6 sites in Japan, South Korea
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Triple Negative Breast Cancer (TNBC)
QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine
This is a randomized open-label phase 2 study to evaluate the efficacy and safety (as assessed by pCR) of the NANT Neoadjuvant TNBC Vaccine regimen (experimental arm) compared to the SoC dose-dense regimen of…
- Trial name
- TNBC (NCT03554109)
- Testing
- Leucovorin, 5-Fluorouracil, Aldoxorubicin HCl
- Where
- United States
- Sponsor
- ImmunityBio, Inc.
Solid Tumor, Colorectal Cancer
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or…
- Conditions
- Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer
- Trial name
- NCT03872947
- Testing
- TRK-950, Irinotecan, Leucovorin
- Where
- 14 sites in United States, France
- Volunteers
- 138 people
- Sponsor
- Toray Industries, Inc
Neoplasms, Head and Neck
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this study is to evaluate if the addition of GSK3359609 to pembrolizumab in combination with 5FU-platinum based chemotherapy improves the efficacy of the pembrolizumab combination with 5FU-platinum based…
- Trial name
- INDUCE-4 (NCT04428333)
- Testing
- Feladilimab, Pembrolizumab, Platinum based chemotherapy
- Where
- 71 sites in United States, Argentina and 17 more
- Volunteers
- 117 people
- Sponsor
- GlaxoSmithKline
Metastatic Pancreatic Cancer
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
The study is an open label, randomized phase 3 study of MM-398 with or without 5-Fluorouracil (5-FU) and Leucovorin (also known as folinic acid), versus 5-FU and leucovorin in metastatic pancreatic cancer patients who have…
- Trial name
- NAPOLI-1 (NCT01494506)
- Testing
- MM-398, 5 Fluorouracil, Leucovorin
- Where
- 79 sites in United States, Argentina and 13 more
- Volunteers
- 417 people
- Sponsor
- Merrimack Pharmaceuticals
Metastatic Colorectal Cancer
Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer
This is a Phase III, randomized, two arms, double-blind (patient and assessor blinded), parallel active non inferiority controlled clinical trial with a 2:1 allocation.
- Trial name
- NCT03288987
- Testing
- Bevacizumab + FOLFIRI-3
- Where
- 22 sites in Iran
- Volunteers
- 126 people
- Sponsor
- AryoGen Pharmed Co.
Colorectal Cancer
PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
The purpose of this study is to assess whether treatment with the study drug, panitumumab given concomitantly with every 2 (Q2) week oxaliplatin-based chemotherapy and bevacizumab improves progression-free survival (PFS) compared…
- Trial name
- NCT00115765
- Testing
- Oxaliplatin Based Chemotherapy, Panitumumab, Irinotecan Based Chemotherapy
- Volunteers
- 1,053 people
- Sponsor
- Amgen
Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC)
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
The goal of this interventional clinical study is to learn the safety and preliminary efficacy of XH001 injection (Personalized mRNA tumor neoantigen vaccine) combined with standard adjuvant treatment in treating patients with…
- Conditions
- Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC), Hepatocellular Carcinoma (HCC), Gastric Cancer (GC)
- Trial name
- NCT07594964
- Testing
- XH001 Injection, mFOLFIRINOX Treatment Regimen
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Shenzhen Xinhe Biomedical
Pancreatic Cancer, Colorectal Cancer
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
This is a Phase 1 multi-center study to assess the safety and efficacy of TGR-1202 as a single agent or in combination with nab-paclitaxel + gemcitabine or with FOLFOX in patients with select relapsed or refractory solid tumors.
- Conditions
- Pancreatic Cancer, Colorectal Cancer, Rectal Cancer, Gastric Cancer
- Trial name
- NCT02574663
- Testing
- TGR-1202, nab-paclitaxel + gemcitabine, Oxaliplatin + Folinic acid + Fluorouracil
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- TG Therapeutics, Inc.
Breast Cancer
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer
This study will assess the efficacy and safety of adding Herceptin to a paclitaxel-containing regimen followed by cyclophosphamide/methotrexate/fluorouracil (CMF) chemotherapy in women with locally advanced breast cancer and…
- Trial name
- NCT01998906
- Testing
- Trastuzumab, Doxorubicin, Paclitaxel
- Where
- 36 sites in Austria, Germany and 4 more
- Volunteers
- 330 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer
This was a phase Ib study of PDR001 in combination with bevacizumab and mFOLFOX6 as first line therapy in patients with metastatic microsatellite stable (MSS) colorectal cancer.
- Trial name
- NCT03176264
- Testing
- PDR001, bevacizumab, mFOLFOX6
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors
A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors
hPV19 is a monoclonal antibody (mAb) directed against vascular endothelial growth factor (VEGF). hPV19 binds to human VEGF with unique binding site on VEGF different from that of Bevacizumab(Avastin) and inhibits the binding of…
- Trial name
- NCT03503604
- Testing
- hPV19 mAb, 5-Fluorouracil, Oxaliplatin
- Where
- China
- Volunteers
- 18 people
- Sponsor
- SuZhou Stainwei Biotech Inc.
Melanoma, Prostate Cancer
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with…
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- IVY (NCT02009449)
- Testing
- Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
- Where
- 10 sites in United States
- Volunteers
- 353 people
- Sponsor
- Eli Lilly and Company
Neoplasm Metastasis, Colorectal Cancer
Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)
This is an open label, randomized, controlled, multicenter phase II study comparing 5-FU/FA + oxaliplatin (FOLFOX-4) + cetuximab versus 5-FU/FA + oxaliplatin as first-line treatment for epidermal growth factor receptor…
- Trial name
- OPUS (NCT00125034)
- Testing
- Cetuximab, Oxaliplatin
- Where
- 78 sites in Austria, Belgium and 11 more
- Volunteers
- 344 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Gastric Cancer
Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer
Primary Objective: To compare the 3-year progression free survival (PFS) in the two treatment arms. Secondary Objectives: Overall survival (OS). Postoperative pathological stage and R0 (complete) resection rate.
- Trial name
- PRODIGY (NCT01515748)
- Testing
- Docetaxel (XRP6976), Oxaliplatin (SR96669), S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)
- Where
- South Korea
- Volunteers
- 530 people
- Sponsor
- Sanofi
Pancreatic Ductal Adenocarcinoma
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
Some people with pancreatic ductal cancer (PDAC) have a protein called Claudin 18.2 (CLDN18.2) in their tumor. ASP2138 is thought to work by binding to CLDN18.2 and a protein on a type of immune cell called a T-cell.
- Trial name
- NCT07024615
- Testing
- ASP2138, Oxaliplatin, Leucovorin
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Hepatocellular Carcinoma, Neoplasms
DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma
Evaluation of DC-CIK cells combined TACE treatment for HCC
- Conditions
- Hepatocellular Carcinoma, Neoplasms, Digestive System Neoplasms
- Trial name
- NCT02487017
- Testing
- Transcatheter Arterial Chemoembolization (TACE), DC-CIK
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen Hornetcorn Bio-technology Company, LTD
Metastatic Colorectal Cancer
A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
The primary objective of this study is to demonstrate equivalence of pharmacokinetic properties, and comparability of safety and immunogenicity parameters of RPH-030 and Vectibix® following a single (first) intravenous…
- Trial name
- NCT07543744
- Testing
- RPH-030, Vectibix®, Irinotecan
- Where
- 26 sites in Russia
- Volunteers
- 180 people
- Sponsor
- R-Pharm
Stomach Neoplasms
Taxotere New Indication - Gastric Cancer Treatment Registration Trial
Primary objective: To detect a statistically significant increase in time to progression (TTP) of disease for the test group (Taxotere® [Docetaxel] combined with cisplatin and 5-fluorouracil [TCF]) relative to the control group…
- Trial name
- NCT00811447
- Testing
- 5-fluorouracil, Cisplatin, Docetaxel
- Where
- China
- Volunteers
- 243 people
- Sponsor
- Sanofi